Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial.
Blood tests tracking tumor DNA may help predict which soft-tissue sarcoma patients need additional treatment after surgery.
This PubMed record reports: These findings support prospective ctDNA-guided interventional trials in STS. The finding is retained for rapid triage and requires downstream evidence review before clinical interpretation.
What the study was
- Study design
- Randomized controlled trial
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Why it surfaced
Retained because its randomized controlled trial evidence is relevant to Early cancer detection (liquid biopsy, ctDNA, cfDNA); scoring is conservative for the available metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.